Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 10, 2023, to disclose an expected acquired in-process research and development (IPR&D) charge for the first quarter of 2023. This charge is primarily related to an upfront payment for their collaboration and license agreement with Sonoma Biotherapeutics, Inc. The company anticipates a pre-tax IPR&D charge of approximately $56 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $0.42 for the quarter. While this charge is a notable event impacting short-term profitability per share, investors should note that such IPR&D charges are inherently unpredictable and are not typically forecasted by the company. The disclosed figures are preliminary estimates and are subject to finalization of the company's financial closing procedures. Investors should monitor future filings for finalized financial results and strategic updates regarding the Sonoma Biotherapeutics collaboration.
Key Highlights
- 1Regeneron anticipates a $56 million pre-tax acquired IPR&D charge for Q1 2023.
- 2This charge is primarily linked to an upfront payment for the Sonoma Biotherapeutics collaboration.
- 3The IPR&D charge is expected to reduce Q1 2023 EPS (both GAAP and non-GAAP) by approximately $0.42.
- 4Acquired IPR&D charges are not typically forecasted by Regeneron due to their unpredictable nature.
- 5The disclosed financial figures are preliminary and subject to change upon finalization of Q1 2023 financial closing procedures.
- 6The filing serves as an update on the financial impact of a previously announced strategic agreement.